R&D Why drug delivery is biotech’s overlooked challenge – and it... Delivery innovations don’t just improve outcomes – they reshape the entire therapy ecosystem.
News Protego's $130m for amyloidosis drug, and other financings Our latest crop of biotech financings has nine-figure rounds for Protego and Triana, with Excelsior Sciences and SciNeuro also raising new funds.
News Veraxa says delayed US listing is back on track Swiss biotech Veraxa's listing on the Nasdaq, delayed by the record 43-day US government shutdown, should now complete in the first quarter of 2026.
News ADC specialist Solve raises $120m, and other biofinancings Our round-up of biofinancings is led by a $120m round for ADC specialist Solve, with Aspen, Artios, Profluent, and Gate Bioscience also raising funds.
News Sofinnova Partners raises €650m for early-stage biotechs European life sciences venture capital company Sofinnova Partners has closed its latest fund, Sofinnova Capital XI, raising €650 million.
News Medicxi raises €500m for latest biotech fund Medicxi closes its fifth round, raising €500m for 'asset-centric' firms at all stages of development and taking the total raised in 10 years to €2bn+.
News CHMP decision levels the playing field for GSK's RSV jab GSK's RSV vaccine is poised for EU approval in all adults aged 18 and over, bringing it into line with rival shots from Pfizer and Moderna.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
